Back to Journals » Drug, Healthcare and Patient Safety » Volume 4
Evaluation of medication package inserts in Saudi Arabia
Authors Al-Aqeel S
Received 22 December 2011
Accepted for publication 10 February 2012
Published 26 March 2012 Volume 2012:4 Pages 33—38
DOI https://doi.org/10.2147/DHPS.S29402
Review by Single anonymous peer review
Peer reviewer comments 3
Sinaa A Al-aqeel
Clinical Pharmacy Department, King Saud University, Riyadh, Kingdom of Saudi Arabia
Purpose: The aim of this study was to examine if package inserts (PIs) supplied with prescribed and over-the-counter medications in Saudi Arabia contain information relevant for the safe and appropriate use of these medications.
Methods: Sixty PIs for prescription-only medications (n = 37) and over-the-counter medications (n = 23) were evaluated against a set of safety criteria compiled from the literature.
Results: Analyzed PIs were defective in many aspects. Particularly of concern were unclear dosage instructions, lack of measures to be taken when an administrative error was made, inappropriate presentation of side effects, and lack of measures to be taken if serious side effects occurred.
Conclusion: This study indicated that information relevant to the safe and appropriate use of medications was not uniformly mentioned in the PIs analyzed. To avoid medication errors due to deficits in the current PIs, we recommend improvement in the existing PIs based on best practice for information content and design.
Keywords: drug information, patient education, patient information leaflets, package inserts
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.